Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.

Cook JA. et al, (2025), Lancet Haematol, 12, e294 - e303

Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 45 - 46

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44

Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial.

Hopewell S. et al, (2024), BMJ Open, 14

The protocol of a clinical effectiveness trial comparing standard step up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomised controlled trial

WATSON M. et al, (2024), Therapeutic Advances in Musculoskeletal Disease

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2024), Lancet Rheumatol, 6, e92 - e104

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.

Barber VS. et al, (2023), BMJ Open, 13

Optimising Psoriatic Arthritis Therapy with Immunological Methods to Increase Standard Evaluation: The protocol of an open-label multi-centre, parallel-group, two arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.

RICHARDS D., (2023), BMJ Open

HOW SHOULD WE BEST MEASURE PARTICIPANT-REPORTED `AVERAGE HAND PAIN': COMPARISON OF TWO METHODS FROM A RANDOMIZED PLACEBO-CONTROLLED FEASIBILITY STUDY OF POST-MENOPAUSAL WOMEN WITH HAND OSTEOARTHRITIS

Williams JA. et al, (2023), OSTEOARTHRITIS AND CARTILAGE, 31, S187 - S188

Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.

Williams JAE. et al, (2022), Lancet Rheumatol, 4, e725 - e737

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2022), Lancet Respir Med

Two-week interruption in methotrexate treatment versus treatment continued as usual and COVID-19 booster immunity in adults with inflammatory conditions (VROOM study): a randomised open label, superiority trial

Abhishek A. et al, (2022), The Lancet Respiratory Medicine

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).

Abhishek A. et al, (2022), BMJ Open, 12

HAND OSTEOARTHRITIS: INVESTIGATING PAIN EFFECTS IN A RANDOMISED PLACEBO-CONTROLLED FEASIBILITY STUDY OF ESTROGEN-CONTAINING THERAPY (HOPE-E): REPORT ON THE PRIMARY FEASIBILITY OUTCOMES

Williams JAE. et al, (2022), ANNALS OF THE RHEUMATIC DISEASES, 81, 1616 - 1617

Is Treating Painful Hand Osteoarthritis with Hormone Replacement Therapy Feasible? Primary Results from a Randomised Controlled Trial in Post-menopausal Women

Williams J. et al, (2022), ARTHRITIS & RHEUMATOLOGY, 74, 3763 - 3765

Hand Osteoarthritis: investigating Pain Effects of estrogen-containing therapy (HOPE-e): a protocol for a feasibility randomised placebo-controlled trial.

Marian IR. et al, (2021), Pilot Feasibility Stud, 7

Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.

Rombach I. et al, (2021), Trials, 22

A Multicentre Observational Psoriatic Arthritis Cohort Study Addressing Real-life Outcomes of a Treat to Target Approach in Routine Clinical Practice.

Coates L. et al, (2021)

Load More

Include forthcoming?